<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6439212/results/search/test_trace/results.xml">
  <result pre="of approved anti-HBV drugs have some therapeutic limitations. While long-term" exact="treatment" post="with HBV Pol inhibitors, the nucleot(s)ide analogs (e.g., lamivudine,"/>
  <result pre="natural products may also modulate the host immune response against" exact="infection" post="(Kurokawa et al., 2010). In line with this, several"/>
  <result pre="line, HepG2.2.15 is one of the established systems for preliminary" exact="screening" post="of anti-HBV drugs in vitro. The in silico molecular"/>
  <result pre="Based on the cytotoxicity results, and previously reported assays, the" exact="treatment" post="dose of 10 μg/ml was chosen for all pure compounds"/>
  <result pre="was repeated to confirm the reproducibility. 2.7 Assessment of combination" exact="treatment" post="Quercetin (10 μg/ml) was further assessed for its enhanced anti-HBV"/>
  <result pre="using FuGENE6 (Promega, USA) in a 48-well culture plate, following" exact="treatment" post="(10 μg/ml; in triplicate) with all compounds, including DMSO (0.1%)"/>
  <result pre="docking The modeled HBV Pol was used as receptor for" exact="screening" post="the binding modes of antiviral natural compounds, including lamivudine"/>
  <result pre="including lamivudine (Fig. 1) in Autodock Vina and PyRx virtual" exact="screening" post="tools (Trott and Olson, 2010, Dallakyan and Olson, 2015)."/>
  <result pre="and 5) study, using HepG2.2.15 cells (Fig. 2). Notably, prolonged" exact="treatment" post="beyond day 5 did not show any significant effect,"/>
  <result pre="(50%) &amp;gt; β-sitosterol (51.5%) &amp;gt; hesperidin (39.5%) as compared to untreated control. Notably, further" exact="treatment" post="with the maximal 50 μg/ml dose did not suppress HBsAg"/>
  <result pre="on HBeAg production for five days (Fig. 3). Notably, prolonged" exact="treatment" post="beyond day 5 did not show any significant effect"/>
  <result pre="means of three determinations. 3.4 Enhanced anti-HBV effect of combination" exact="treatment" post="Compared to quercetin treatment alone, its combinations (1:1, w/w)"/>
  <result pre="3.4 Enhanced anti-HBV effect of combination treatment Compared to quercetin" exact="treatment" post="alone, its combinations (1:1, w/w) with individual compounds (baccatin"/>
  <result pre="mixture of all compounds. Fig. 4 Antiviral effects of combination" exact="treatment" post="on HBV replication, showing inhibition of HBeAg expressions relative"/>
  <result pre="the levels of Renilla-luciferase protein synthesis in HepG2.2.15 cells upon" exact="treatment" post="with the optimal dose (10 μg/ml) of all anti-HBV natural"/>
  <result pre="we performed molecular docking using Autodock Vina in PyRx virtual" exact="screening" post="tool. The amino acid residues and the type of"/>
  <result pre="the first generation nucleot(s)ide-based anti-retroviral drug generally used in the" exact="treatment" post="of HIV/AIDS and CHB. Docking of lamivudine (as control)"/>
  <result pre="and in silico molecular modeling represent first and fastest drug" exact="screening" post="steps. Absence of a robust cell culture system for"/>
  <result pre="line, HepG2.2.15 is one of the established systems for preliminary" exact="screening" post="of anti-HBV drugs. In the present study, the anti-HBV"/>
  <result pre="virus constituents from solanum erianthumPlanta Med.7820121190–1190 CunninghamA.L.DwyerD.E.DowtonD.N.Viral markers in HIV" exact="infection" post="and AIDSJ. Acquir. Immune Defic. Syndr.61993S32S358426300 DagaP.R.DuanJ.S.DoerksenR.J.Computational model of"/>
  <result pre="dynamics and docking to understand resistant mutationsProtein Sci.19201079680720162615 DallakyanS.OlsonA.J.Small-molecule library" exact="screening" post="by docking with PyRxMeth. Mol. Biol.12632015243250 FlekhterO.B.BorekoE.I.NigmatullinaL.P.PavlovaN.I.MedvedevaN.I.Synthesis and antiviral"/>
 </snippets>
</snippetsTree>
